AI Insight
Researchers used human donor lungs in an ex vivo perfusion system to model two types of early lung injury relevant to Acute Respiratory Distress Syndrome (ARDS) - direct injury via airway exposure and indirect injury via blood vessel exposure to bacterial lipopolysaccharide. Proteomic analysis at 4 hours revealed distinct molecular signatures: direct injury showed more neutrophil activity and tissue remodeling, while indirect injury displayed greater complement activation and endothelial damage. By matching these injury signatures against a drug database, the team identified several potential therapeutic targets including JAK/STAT, PI3K/AKT/mTOR, and histone deacetylase pathways that could be tested for treating ARDS.
Why it matters
ARDS has no approved targeted treatments and kills 35-40% of patients. This platform allows testing of injury-specific therapies on intact human lung tissue during the critical early hours when interventions might be most effective, potentially accelerating drug discovery for this deadly condition.
Understand the Science
⚠️ Preprint – Noch nicht peer-reviewed
Dieser Artikel wurde noch nicht von unabhängigen Experten begutachtet. Die Ergebnisse sind vorläufig und sollten mit Vorsicht interpretiert werden.
Acute Respiratory Distress Syndrome (ARDS) remains highly morbid and lacks approved disease-modifying pharmacotherapies. Direct (pulmonary) and indirect (extrapulmonary) insults may initiate biologically distinct early injury programs, but human tissue-level evidence from the first hours is scarce. Here we establish a paired, acellular ex vivo lung perfusion (EVLP) platform using human donor lungs unsuitable for transplantation to model direct (endobronchial) and indirect (perfusate) lipopolysaccharide (LPS) injury within the same donor. We profiled lung tissue proteomes at 4 h post-insult and performed therapeutic nomination by querying proteomics-derived injury signatures against the CLUE L1000 perturbational compendium with independent cross-platform validation. Both models developed histological injury and robust cytokine release. Direct injury preferentially enriched neutrophil degranulation, extracellular matrix remodelling and metabolic reprogramming modules, whereas indirect injury showed prominent complement/coagulation perturbation with greater endothelial activation markers in perfusate. Cross-platform prioritisation converged on tractable signalling and epigenetic axes, including JAK/STAT, PI3K/AKT/mTOR, SYK, CDK and HDAC inhibitor classes – yielding a tiered shortlist for EVLP intervention testing. This intact human lung perturbation platform enables injury-stratified mechanistic inference and therapeutic prioritisation in early lung injury relevant to ARDS.